Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Angeles Wealth Management LLC

Angeles Wealth Management LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 3,943 shares of the medical research company’s stock after purchasing an additional 22 shares during the period. Angeles Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $2,051,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $52,000. Kestra Private Wealth Services LLC raised its stake in shares of Thermo Fisher Scientific by 10.4% during the 4th quarter. Kestra Private Wealth Services LLC now owns 11,914 shares of the medical research company’s stock valued at $6,198,000 after buying an additional 1,118 shares during the last quarter. Howland Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 2.7% in the fourth quarter. Howland Capital Management LLC now owns 79,771 shares of the medical research company’s stock worth $41,530,000 after buying an additional 2,098 shares during the last quarter. Empowered Funds LLC raised its position in Thermo Fisher Scientific by 17.8% during the fourth quarter. Empowered Funds LLC now owns 11,408 shares of the medical research company’s stock valued at $5,935,000 after acquiring an additional 1,720 shares in the last quarter. Finally, Farmers & Merchants Investments Inc. boosted its position in Thermo Fisher Scientific by 4.4% in the 4th quarter. Farmers & Merchants Investments Inc. now owns 4,082 shares of the medical research company’s stock worth $2,124,000 after purchasing an additional 173 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $571.44 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The business’s 50 day moving average price is $547.34 and its 200 day moving average price is $572.26. The company has a market cap of $218.58 billion, a price-to-earnings ratio of 34.57, a PEG ratio of 3.18 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the transaction, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,125 shares of company stock valued at $11,231,699. 0.34% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on TMO shares. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Scotiabank increased their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research note on Monday, February 3rd. Evercore ISI reduced their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Royal Bank of Canada cut their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Citigroup increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $658.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.